Visual hallucination in Parkinson's disease with FDG PET

被引：73
|
作者：
Nagano-Saito, A
Washimi, Y
Arahata, Y
Iwai, K
Kawatsu, S
Ito, K
Nakamura, A
Abe, Y
Yamada, T
Kato, T
Kachi, T
机构：
[1] Natl Ctr Geriatr & Gerontol, Dept Brain Sci & Mol Imaging, Natl Inst Longev Sci, Obu, Aichi 4748522, Japan
[2] Chubu Natl Hosp, Dept Neurol, Obu, Japan
来源：
MOVEMENT DISORDERS | 2004年 / 19卷 / 07期
关键词：
Parkinson's disease; visual hallucination; F-18]fluorodeoxyglucose; FDG; positron emission tomography (PET);
D O I：
10.1002/mds.20129
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
To determine the characteristics of cerebral glucose metabolism in Parkinson's disease patients with visual hallucinations, group comparison studies using [F-18]fluorodeoxyglucose positron emission tomography were performed. Nondemented Parkinson's disease patients in advanced stages were classified into two groups: (1) patients without visual hallucinations; (2) patients with visual hallucinations. Compared to patients without hallucinations. the relative regional cerebral glucose metabolic rate was greater in the frontal areas in patients with visual hallucinations, and the increase reached a significant level in the left superior frontal gyrus. Relative frontal hypermetabolism may be a feature of Parkinson's disease patients with visual hallucinations. (C) 2004 Movement Disorder Society.
引用
收藏
页码：801 / 806
页数：6
相关论文
共 50 条
  • [31] Single-subject FDG PET patterns and cognitive dysfunctions in Parkinson's disease
    Pilotto, A.
    Premi, E.
    Caminiti, S. P.
    Presotto, L.
    Turrone, R.
    Alberici, A.
    Paghera, B.
    Borroni, B.
    Perani, D.
    Padovani, A.
    MOVEMENT DISORDERS, 2016, 31 : S461 - S461
  • [32] Clinical utility of FDG PET in Parkinson’s disease and atypical parkinsonism associated with dementia
    Zuzana Walker
    Federica Gandolfo
    Stefania Orini
    Valentina Garibotto
    Federica Agosta
    Javier Arbizu
    Femke Bouwman
    Alexander Drzezga
    Peter Nestor
    Marina Boccardi
    Daniele Altomare
    Cristina Festari
    Flavio Nobili
    European Journal of Nuclear Medicine and Molecular Imaging, 2018, 45 : 1534 - 1545
  • [33] Incidence of RBD and hallucination in patients affected by Parkinson's disease
    Onofrj, M.
    Iacono, D.
    Luciano, A. L.
    Armellino, K.
    Bonanni, L.
    Anzellotti, F.
    Varanese, S.
    Thomas, A.
    JOURNAL OF THE NEUROLOGICAL SCIENCES, 2006, 248 (1-2) : 278 - 278
  • [34] Electroconvulsive therapy for olfactory hallucination in a patient with Parkinson's disease
    Hoshiyama, E.
    Kadowaki, T.
    Suzuki, K.
    Tatsumoto, M.
    Miyamoto, T.
    Hirata, K.
    MOVEMENT DISORDERS, 2007, 22 : S72 - S72
  • [35] Parkinson's disease with visual hallucination: optic radiation abnormalities on phase difference-enhanced imaging (PADRE)
    Miyata, M.
    Kakeda, S.
    Yoneda, T.
    Narimatsu, H.
    Sato, T.
    Okada, K.
    Adachi, H.
    Korogi, Y.
    MOVEMENT DISORDERS, 2017, 32
  • [36] Visual exploration in Parkinson's disease and Parkinson's disease dementia
    Archibald, Neil K.
    Hutton, Sam B.
    Clarke, Michael P.
    Mosimann, Urs P.
    Burn, David J.
    BRAIN, 2013, 136 : 739 - 750
  • [37] Visual symptoms in Parkinson's disease and Parkinson's disease dementia
    Archibald, Neil K.
    Clarke, Mike P.
    Mosimann, Urs P.
    Burn, David J.
    MOVEMENT DISORDERS, 2011, 26 (13) : 2387 - 2395
  • [38] The study of 18F-FDG PET / CT imaging in the value on Parkinson's disease
    Mao, Z.
    Xue, Z.
    MOVEMENT DISORDERS, 2018, 33 : S709 - S710
  • [39] The neural substrates of bradykinesia and tremor in uncomplicated Parkinson's Disease assessed with PET and resting FDG
    Lozza, C
    Baron, JC
    Marie, RM
    NEUROIMAGE, 2001, 13 (06) : S811 - S811
  • [40] Gene therapy for Parkinson's Disease with AAV-GAD: Interim FDG PET results
    Feigin, A
    Tang, C
    Ma, YL
    Dhawan, V
    During, M
    Kaplitt, M
    Eidelberg, D
    NEUROLOGY, 2006, 66 (05) : A48 - A48
12345